Grifols, S.A. (NASDAQ:GRFS) Sees Large Drop in Short Interest

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 2,710,000 shares, a decrease of 28.9% from the February 28th total of 3,810,000 shares. Based on an average daily volume of 991,800 shares, the short-interest ratio is presently 2.7 days. Currently, 1.1% of the company's stock are short sold.

Wall Street Analyst Weigh In

Separately, Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Grifols Stock Down 5.1 %

Shares of GRFS stock traded down $0.38 during trading on Thursday, reaching $7.11. The company's stock had a trading volume of 1,214,317 shares, compared to its average volume of 1,037,152. Grifols has a one year low of $5.79 and a one year high of $9.96. The business has a fifty day moving average price of $7.55 and a 200-day moving average price of $8.01. The company has a market cap of $4.89 billion, a price-to-earnings ratio of 6.08 and a beta of 0.35. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital World Investors increased its position in shares of Grifols by 0.7% in the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock valued at $157,239,000 after acquiring an additional 154,358 shares during the last quarter. Brandes Investment Partners LP grew its stake in Grifols by 3.0% in the fourth quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock valued at $152,491,000 after purchasing an additional 592,096 shares in the last quarter. Black Creek Investment Management Inc. increased its position in shares of Grifols by 1.3% during the 4th quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company's stock worth $83,715,000 after purchasing an additional 141,615 shares during the last quarter. Soleus Capital Management L.P. raised its stake in shares of Grifols by 46.1% during the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company's stock worth $49,144,000 after purchasing an additional 2,083,722 shares in the last quarter. Finally, Whitebox Advisors LLC raised its stake in shares of Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company's stock worth $37,487,000 after purchasing an additional 1,519,093 shares in the last quarter.

Remove Ads

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.